{"id":"W4295816936","doi":"10.1016/j.annonc.2022.07.179","title":"144P Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo; Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Anastrozole; Palbociclib; Internal medicine; Clinical endpoint; Breast cancer; Oncology; Stage (stratigraphy); Gynecology; Cancer; Urology; Gastroenterology; Metastatic breast cancer; Tamoxifen; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001501332,0.00141672,0.002463714,0.0004441282,0.0002261205,0.001158338,0.0007122138,0.0009732646,0.003586272],"category_scores_gemma":[0.001661611,0.0005596778,0.003447986,0.0005319394,0.0005963563,0.0007638871,0.0005435878,0.002268749,0.000640112],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001188907,"about_ca_system_score_gemma":0.00112931,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003113849,"about_ca_topic_score_gemma":0.009627626,"domain_scores_codex":[0.9994006,0.0003296602,0.00004132005,0.00009203432,0.00004968886,0.0000866271],"domain_scores_gemma":[0.9995657,0.0001261685,0.0001031793,0.0000586254,0.0000277774,0.0001186067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9597449,0.0009170966,0.00278746,0.000868394,0.005731379,0.00004481196,0.0000430717,0.0009331837,0.002710805,0.0001470515,0.001580023,0.02449181],"study_design_scores_gemma":[0.8827866,0.07570646,0.01892018,0.0002607055,0.01460582,0.0001755428,0.000137487,0.00178227,0.00117609,0.0009061733,0.003479572,0.0000630478],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9703532,0.01952742,0.0007094581,0.001250937,0.0007440107,0.001294021,0.002916386,0.0001268181,0.003077697],"genre_scores_gemma":[0.9866905,0.005292137,0.0006764865,0.0008710485,0.0003157171,0.000906135,0.002596307,0.00003261924,0.002618994],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003586272,"threshold_uncertainty_score":0.01199722,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0236514411366035,"score_gpt":0.3379894408180784,"score_spread":0.3143379996814749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}